Social Media Press Releases
RSSShowing Press Releases with Tag: reverse genetics
9/24/2007
MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
» read more8/23/2007
MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
» read more3/29/2007
MedImmune Licenses Reverse Genetics Technology to sanofi pasteur for Use in Influenza Vaccine Production
» read more12/20/2006
MedImmune Licenses Reverse Genetics Technology to CSL for Use in Influenza Vaccine Production
» read more12/06/2006
MedImmune Reconfirms 2009 Financial Targets of $2 Billion in Revenues and $2.00 in Earnings Per Diluted Share, Excluding Share-Based Compensation Expense, at 2006 Analyst Day
» read more11/09/2006
MedImmune Files Investigational New Drug Application for Cell Culture-Based Influenza Vaccine
» read more7/06/2006
MedImmune Receives FDA Approval to Use Reverse Genetics Technology for FluMist® Vaccine Production
» read more6/29/2006
MedImmune Broadens Efforts to Develop Vaccines to Help Prevent RSV and Other Important Pediatric Respiratory Diseases
» read more6/15/2006
MedImmune and National Institutes of Health Begin Clinical Testing of a Live, Attenuated Intranasal Vaccine Against an H5N1 Avian Influenza Virus
» read more5/04/2006
MedImmune Awarded $170 Million, Five-Year Contract From U.S. Health and Human Services to Develop Cell-Based Influenza Vaccines
» read more12/27/2005
FDA Approves MedImmune’s State-of-the-Art Influenza Vaccine Manufacturing Facility
» read more12/12/2005
